TY - JOUR
T1 - Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization
AU - Lanzetta, Paolo
AU - Battaglia Parodi, Maurizio
AU - Ambesi-Impiombato, Massimo
AU - Ravalico, Giuseppe
AU - Bandello, Francesco
PY - 2004/10
Y1 - 2004/10
N2 - Background: Photodynamic therapy is a relatively new modality for the treatment of subfoveal choroidal neovascularization (CNV). An unusual response to verteporfin therapy of myopic CNVs is reported. Methods: Out of 187 CNVs secondary to pathologic myopia treated with photodynamic therapy, three eyes manifested two separate foci of CNV before treatment. The three eyes were treated with verteporfin therapy according to the standard protocol, using a single spot of light that covered both neovascular fronds. Results: All the three eyes showed neo vascular bridging of the two separate neovascular complexes 1 month after treatment. Conclusions: Eyes with multiple foci of myopic CNV may show unexpected outcomes after verteporfin therapy. Several factors, such as changes of the retinal pigment epithelium and choroidal vasculature involved in the treatment and enhanced expression of vascular endothelial growth factor, may play a role.
AB - Background: Photodynamic therapy is a relatively new modality for the treatment of subfoveal choroidal neovascularization (CNV). An unusual response to verteporfin therapy of myopic CNVs is reported. Methods: Out of 187 CNVs secondary to pathologic myopia treated with photodynamic therapy, three eyes manifested two separate foci of CNV before treatment. The three eyes were treated with verteporfin therapy according to the standard protocol, using a single spot of light that covered both neovascular fronds. Results: All the three eyes showed neo vascular bridging of the two separate neovascular complexes 1 month after treatment. Conclusions: Eyes with multiple foci of myopic CNV may show unexpected outcomes after verteporfin therapy. Several factors, such as changes of the retinal pigment epithelium and choroidal vasculature involved in the treatment and enhanced expression of vascular endothelial growth factor, may play a role.
UR - http://www.scopus.com/inward/record.url?scp=8444242498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8444242498&partnerID=8YFLogxK
U2 - 10.1007/s00417-004-0904-0
DO - 10.1007/s00417-004-0904-0
M3 - Article
C2 - 15221306
AN - SCOPUS:8444242498
VL - 242
SP - 840
EP - 844
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
SN - 0721-832X
IS - 10
ER -